Taiho has reupped its commitment to the venture firm’s second fund, which is also backed by EA Pharma and Senju and which has closed at $95m.
US-headquartered venture capital firm Remiges Ventures has closed its second fund at $95m with contributions from investors including pharmaceutical groups EA Pharma, Senju Pharmaceutical and Taiho Pharmaceutical.
Remiges BioPharma Fund II’s limited partners (LPs) also include healthcare-focused investment firm 1Globe Capital.
Taiho committed up to $30m for the fund in 2019. It provided the same amount for Remiges’ first vehicle five years earlier, investing alongside peer Sumitomo Dainippon Pharma, and the fund subsequently closed at $80m in 2017.
…
